Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Future role of CAR-T in myeloma

Hermann Einsele • 18 Jun 2021
EHA 2021
Multiple Myeloma CAR-T

Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, discusses the future role of chimeric antigen receptor T-cell (CAR-T) therapy in the treatment of multiple myeloma. Prof. Einsele talks on the efficacy and tolerability of CAR-T in heavily pretreated patients, commenting on high response rates and complete response rates, and the potential of CAR-T therapy to be a cure for myeloma if used in earlier settings. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Hermann Einsele

2:44
Moving CAR-T into earlier lines of therapy in multiple myeloma
Hermann Einsele • 17 Feb 2024
0:45
CAR T-cell therapy in lenalidomide-refractory multiple myeloma
Hermann Einsele • 17 Feb 2024
1:19
Sequencing bispecific antibodies and CAR-T therapy & the evolving role of bispecifics in myeloma
Hermann Einsele • 26 Jun 2023
8:16
Results from CARTITUDE-4: cilta-cel for lenalidomide-refractory multiple myeloma
Hermann Einsele • 26 Jun 2023

Related Videos

2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals